EST NLS Pharmaceutics (NLSP) files $75M mixed securities shelfMaximize Your Portfolio with Data Driven Insights:Leverage the power of ...

NLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous ...

Researchers from the Monash Milk Team have published a new study demonstrating the power of human milk as a highly effective ...

A Hunt Valley drug manufacturing company with more than 300 employees has been acquired by a Fortune 500 firm.

NLS Pharmaceutics (NLSP) and Kadimastem, a clinical-stage cell therapy company specializing in the treatment of neurodegenerative diseases and ...

PureTech Founded Entity Seaport Therapeutics Announces Publication of New Research Demonstrating Increased Lymphatic Transport with Glyph Platform ...

With one foot already in the healthcare realm, multi-industry manufacturer Jabil is beefing up its biopharma bona fides with ...

ZURICH and NESS ZIONA, Israel - NLS Pharmaceutics Ltd. (Nasdaq: NLSP) and Kadimastem Ltd. (TASE: KDST) announced plans for a merger, aiming to enhance diabetes treatment by combining their expertise ...

NLS Pharmaceutics stock is trading higher on Friday after the company announced its merger with Kadimastem has been approved by Kadimastem shareholders.

NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system ...

Shareholders of the Israeli bio-pharmaceutical startup, Kadimastem Ltd. approved the companys merger with the Swiss ...